Oct 2026· Bioorganic chemistry (Print)· Vol 183, pp.
110645
· 0 citations· 56 references
Medicine
TL;DR
A GSH-activated theranostic probe, Np-DOX, which links a sulfonamide-containing naphthalimide derivative with the anti-tumor drug doxorubicin (DOX), represents a promising theranostic platform for monitoring drug delivery while exerting potent anticancer activity.
Abstract
The elevated glutathione (GSH) levels in cancer cells present a key opportunity for integrated therapeutic-diagnostic strategies. Leveraging this characteristic, we develop a GSH-activated theranostic probe, Np-DOX, which links a sulfonamide-containing naphthalimide derivative with the anti-tumor drug doxorubicin (DOX). Notably, under excitation at 390 nm and 480 nm, the fluorescence of the naphthalimide moiety and the intrinsic red emission of DOX enable dual-channel real-time imaging of drug release, respectively. Moreover, Np-DOX can effectively distinguish tumor cells from normal cells through marked changes in fluorescence intensity in the dual-emission channels. Furthermore, GSH-triggered activation of Np-DOX allows for the concurrent release of sulfur dioxide (SO2) and DOX, resulting in a synergistic antitumor effect through the combination of SO2 gas therapy and chemotherapy. Therefore, Np-DOX represents a promising theranostic platform for monitoring drug delivery while exerting potent anticancer activity.
Chemotherapeutic agents are often limited by poor tumor-specific accumulation, leading to off-target toxicity, while monochemotherapy frequently results in multidrug resistance and suboptimal treatment outcomes. To address these challenges, we have developed a carbon dot-based nanogel drug delivery system that integrat...
Lei Yue, Jian-Wei Li, Yun-Xiao Zhang et al.· Advanced Healthcare Material...· 0 citations
The development of multimodal combined treatment strategies employing nanomedicine delivery systems effectively addresses the drawbacks of traditional tumor treatment, such as severe side effects, poor therapeutic effects, and high susceptibility to drug resistance. Herein, a folic acid (FA)-functionalized nanoplatform...
Hui-Jia Lei, Yi-Ying Cui, Ji-Cong Chen et al.· ACS Applied Materials and In...· 0 citations
The design and synthesis of a series of donor–acceptor (D–A)-type aggregation-induced emission luminogens (AIEgens) specifically engineered for room temperature phosphorescence (RTP) emission and efficient photodynamic therapy are presented.
Breast cancer treatment is limited by conventional therapies and by the poor photostability and tumor accumulation of photothermal agents such as indocyanine green (ICG). Here, we develop a DNA-based nanosystem, TDN-ICG-Ypy, that undergoes controlled aggregation specifically triggered by the tumor-associated miRNA-21 f...
Wen-Jing Wu, Jun-Xia Wang, Hang Zhao et al.· Journal of Photochemistry an...· 0 citations
Breast cancer is a highly prevalent malignancy, but the conventional single chemotherapy suffers from insufficient therapeutic outcomes. To overcome this challenge, this study developed a dextran-based prodrug nanogel (DDIR) with dual pH/GSH responsiveness to the tumor microenvironment, enabling near-infrared (NIR) flu...
Hypoxia-activated theranostic agents (HATAs) represent a promising strategy for selective visualization and treatment of hypoxic tumor cells. However, their therapeutic efficacy is restricted by limited tumor-targeting capability, inefficient theranostic agent activation and immunosuppressive microenvironment. Herein,...